长春高新(000661) - 2024 Q3 - 季度财报

Revenue and Profit Performance - Revenue for Q3 2024 was 3.75 billion yuan, a decrease of 16.94% year-over-year[3] - Net profit attributable to shareholders for Q3 2024 was 1.07 billion yuan, down 26.37% year-over-year[3] - Total revenue for the first three quarters of 2024 was 10.39 billion yuan, a decrease of 2.75% year-over-year[6] - Net profit attributable to shareholders for the first three quarters of 2024 was 2.79 billion yuan, down 22.8% year-over-year[6] - Total operating income for the current period is RMB 10,387,939,088.74, compared to RMB 10,681,707,158.20 in the previous period[15] - Net profit for the current period is RMB 2,922,032,804.68, down from RMB 3,783,683,465.89 in the previous period[16] - Net profit attributable to the parent company's shareholders is RMB 2,788,885,490.15, compared to RMB 3,612,424,090.35 in the previous period[16] - Basic earnings per share (EPS) for the current period is RMB 6.93, down from RMB 8.98 in the previous period[17] - Diluted earnings per share (EPS) for the current period is RMB 6.83, down from RMB 8.86 in the previous period[17] - Total comprehensive income for the current period is RMB 2,905,178,346.73, compared to RMB 3,776,440,386.98 in the previous period[17] Subsidiary Performance - Subsidiary Jinsai Pharmaceutical achieved revenue of 8.16 billion yuan, a slight increase of 0.55% year-over-year[6] - Subsidiary Baike Biotech's revenue decreased by 17.47% year-over-year to 1.03 billion yuan[6] - Subsidiary Huakang Pharmaceutical's revenue increased by 11.01% year-over-year to 572 million yuan[6] Expenses and Costs - Prepayments increased by 288 million yuan, up 46.43% compared to the beginning of the year, due to increased material procurement and R&D expenses[6] - Management expenses increased by 272 million yuan, up 48.18% year-over-year, due to organizational adjustments and new subsidiary setups[7] - Operating costs for the current period are RMB 6,868,215,904.85, with a significant decrease in cost of sales to RMB 1,495,915,022.13 from RMB 1,611,988,406.57 in the previous period[15] - Sales expenses increased to RMB 3,144,355,406.06 from RMB 2,815,072,002.15 in the previous period[16] - R&D expenses rose to RMB 1,409,774,640.06 from RMB 1,166,638,725.36 in the previous period[16] - Cash paid for employee compensation and benefits increased to RMB 2,494,641,902.15 from RMB 2,009,788,554.87 in the previous year[18] - Cash paid for taxes and fees rose to RMB 1,205,565,821.66 from RMB 1,032,063,428.90 in the same period last year[18] Assets and Liabilities - Total assets as of September 30, 2024, amounted to RMB 31,072,779,833.46, compared to RMB 30,743,650,924.81 at the beginning of the year[12] - Current assets totaled RMB 16,837,490,904.40, a decrease from RMB 18,164,855,480.07 at the beginning of the year[11] - Non-current assets increased to RMB 14,235,288,929.06 from RMB 12,578,795,444.74 at the beginning of the year[12] - Monetary funds decreased to RMB 6,455,232,638.88 from RMB 7,583,812,274.09 at the beginning of the year[10] - Accounts receivable decreased to RMB 3,083,204,426.91 from RMB 3,214,279,382.15 at the beginning of the year[11] - Inventory decreased to RMB 4,564,700,024.88 from RMB 4,956,286,771.35 at the beginning of the year[11] - Fixed assets increased to RMB 4,342,869,424.37 from RMB 3,801,995,117.33 at the beginning of the year[12] - Construction in progress increased to RMB 3,691,287,222.14 from RMB 2,850,236,949.19 at the beginning of the year[12] - Development expenditure increased to RMB 1,462,606,342.70 from RMB 1,157,051,563.35 at the beginning of the year[12] - Total liabilities as of September 30, 2024, included short-term borrowings of RMB 83,809,437.97, down from RMB 144,472,018.39 at the beginning of the year[12] - Long-term loans increased by 677 million yuan, up 383.43% compared to the beginning of the year, due to bank borrowings by subsidiaries[7] Cash Flow - Operating cash flow for the period was RMB 3,095,834,053.88, a decrease from RMB 3,623,708,358.85 in the same period last year[18] - Net cash flow from investing activities was negative RMB 1,790,848,843.66, compared to negative RMB 1,518,183,118.91 in the previous year[19] - Net cash flow from financing activities was negative RMB 2,432,952,574.81, a significant increase in outflow compared to negative RMB 442,453,022.15 in the prior year[19] - Total cash and cash equivalents at the end of the period were RMB 6,410,600,754.19, down from RMB 7,122,084,845.71 at the end of the previous year[19] - Cash received from sales of goods and services is RMB 10,917,920,125.25, up from RMB 10,211,176,454.66 in the previous period[17] - Cash received from other operating activities was RMB 304,963,809.40, a decrease from RMB 344,084,163.57 in the same period last year[18] - Cash outflow for the purchase of fixed assets, intangible assets, and other long-term assets increased to RMB 1,589,851,431.71 from RMB 1,331,047,190.50 in the previous year[19] - Cash received from borrowings increased significantly to RMB 1,018,528,432.85 from RMB 384,412,607.55 in the same period last year[19] Audit and Reporting - The company's third quarter report was not audited[20]